3D Medicines FY26 H1 comprehensive loss narrows 4.47% to RMB 88.5 million; revenue rises 0.6% to RMB 210.5 million

• 3D Medicines posted revenue up 0.6% year on year to RMB 210.5 million, while total comprehensive loss narrowed 4.47% to RMB 88.5 million.
• Gross profit slipped 0.08% to RMB 192.8 million, with gross margin easing 0.6 percentage points to 91.6%.
• R&D expenses fell 23.8% to RMB 63.3 million, while selling and marketing costs rose 6.3% to RMB 118.6 million.
• Cash, FVTPL financial assets and amortized-cost financial assets totaled RMB 482.9 million at June 30, down from December on operating cash outflow.
• NMPA accepted an NDA for Envafolimab plus GEMOX in first-line biliary tract cancer; a Phase III NSCLC perioperative study completed enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3D Medicines Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309948), on August 31, 2026, and is solely responsible for the information contained therein.